Exelixis | EXEL - 资产



金融业
股票价格
USD 70.70
资产
USD 2.51B
现金及等价物
USD 304.77M
销售成本
USD 26.23M
流动资产
USD 1.32B
流动负债
USD 411.88M
债务
USD 162.2M
EBIT
USD 268.42M
EBITDA
USD 275.36M
员工
1.15K
EPS每股收益
USD 0.94
股本和储备
USD 1.83B
销售毛利
USD 632.46M
债务利息支出
USD 23.4M
利息收入
USD 14.32M
市值
USD 20.16B
净收入
USD 218.1M
营业费用
USD 390.27M
营业利润
USD 268.42M
普通股股本
USD 244.68M
PE价格收益
18.43
税前利润
USD 282.79M
销售收入
USD 658.69M
销售和管理费用
USD 154.56M
股票
USD 29.87M
贸易债权人
USD 30.83M
应收帐款人
USD 328.47M


资产 更改 日
Acadia Pharmaceuticals USD 1.79B 51.25M 2026-09
Agios Pharmaceuticals USD 1.06B 44.38M 2026-09
Akebia Therapeutics USD 342.13M 7.53M 2026-09
Amgen USD 96.05B 409M 2026-09
AstraZeneca USD 119.92B 4.09B 2026-09
Bayer EUR 113.47B 6.18B 2026-09
BioMarin Pharmaceutical USD 11.57B 154.21M 2026-09
Bristol-Myers Squibb USD 88.77B 1.14B 2026-09
Cytokinetics USD 1.82B 99.77M 2026-09
Eisai JPY 1.52T 33.49B 2026-09
Eli Lilly USD 148.07B 5.79B 2026-09
Exelixis USD 2.51B 19.26M 2026-09
Genmab DKK 12.52B 139M 2026-06
Glaxosmithkline GBP 71.7B 8.83B 2026-09
Incyte USD 7.29B 585.39M 2026-09
Ionis Pharmaceuticals USD 2.91B 81.91M 2026-09
MacroGenics USD 345.41M 127.54M 2026-06
Merck USD 132.77B 2.97B 2026-09
Moderna USD 13.47B 2.51B 2026-09
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.63B 268.3M 2026-09
Novartis USD 117.15B 4.88B 2026-09
Pfizer USD 204.54B 3.41B 2026-09
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sanofi EUR 129.06B 1.04B 2026-06
Takeda JPY 15.27T 391.77B 2026-09
Ultragenyx Pharmaceutical USD 1.19B 77M 2026-09
Xencor USD 770.5M 45.54M 2026-09